An interventional study of Metformin treatment and Placebo treatment in Impaired Glucose Tolerance and Diabetes Mellitus, Type 2, sponsored by Kristian Karstoft. Completed at 1 site in Denmark. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-09.
Sponsored by Kristian Karstoft · Not applicable, Interventional, and Basic science
Physical activity is a first line treatment for patients with type 2 diabetes (T2D), however, the vast majority of patients with T2D do not achieve satisfying glycemic control with physical activity alone, which is why pharmacological treatment with metformin is most often initiated.
It is known that metformin and exercise both activates 5' adenosine monophosphate-activated protein kinase (AMPK) in skeletal muscle and liver, and the activation of AMPK results in many different metabolic effects, including improvements in glycemic control. Because of this similarity in mechanism of action, an interaction between metformin and exercise is plausible, but knowledge in the area is sparse. Thus, the aim of this study is to assess the effects of acute physical activity with and without concomitant metformin treatment, in order to investigate whether an interaction between the two occur.
Subjects with impaired glucose tolerance will be randomized (1:1) to metformin/placebo treatment in a double-blinded way. Following a treatment run-in period of 17 days, two experimental days (one with acute exercise and one without acute exercise), separated by one week, will be performed in each subject.
This registration concerns a sub-study of another study which has previously been registrered at ClinicalTrials.gov (Unique Protocol ID: H-17012307). The specific outcomes in this registration have not previously been registered.
Exclusion Criteria:
Drug: Metformin treatment
Drug: Placebo treatment
Daily treatment with metformin tablets for 24 days according to the following scheme: Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2
Daily treatment with placebo tablets for 24 days according to the following scheme: Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2
Difference in postprandial glycemic control as assessed by mean blood glucose concentration during a 4 hour mixed-meal tolerance test
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Difference in endogenous glucose production as assessed by rate of infused glucose tracer appearance in blood
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Difference in exogenous glucose uptake as assessed by rate of ingested glucose tracer appearance in blood
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Difference in peripheral glucose uptake as assessed by rate of glucose disappearance from blood
Time frame: Day 17 (no acute exercise [control day]) and 24 (following an acute exercise bout)
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kristian Karstoft